Home > Insider Trading > Filing (0001209191-14-040981)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1428522	Radius Health Inc.	RDUS	Blank Checks (6770)	800145732

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
924223	Ag Biotech Bb	Vordergasse 3 Schaffhausen V8 8200		No	No	Yes	No
1259869	V N Growth Biotech	Snipweg 26 Curacao 00000		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-06-06	589,290	$0.00	589,290	No	4	C	Direct
Common Stock	Acquisiton	2014-06-06	428,459	$0.00	1,017,749	No	4	C	Direct
Common Stock	Acquisiton	2014-06-06	500,029	$0.00	1,517,778	No	4	C	Direct
Common Stock	Acquisiton	2014-06-06	187,262	$0.00	1,705,040	No	4	J	Direct
Common Stock	Acquisiton	2014-06-06	1,000,000	$8.00	2,705,040	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	J	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2014-06-06	122,820	$0.00	589,290	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2014-06-06	97,688	$0.00	428,459	$0.00
Common Stock	Series B-2 Convertible Preferred Stock	Disposition	2014-06-06	65,125	$0.00	500,029	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Radius Health, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.
The Series A-1 Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.798-for-1 basis upon the listing of the Issuer's Common Stock on a national securities exchange and had no expiration date. The Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.386-for-1 basis upon the listing of the Issuer's Common Stock on a national securities exchange and had no expiration date. The Series B-2 Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7,678-for-1 basis upon the listing of the Issuer's Common Stock on a national securities exchange and had no expiration date.
In connection with the listing of the Issuer's Common Stock on a national securities exchange, the Issuer issued shares of its Common Stock to certain of its preferred stock holders in satisfaction of accumulated and unpaid dividends.